title: Comparison of sirolimus-eluting and bare metal stents in coronary bifurcation lesions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease Trial (SCANDSTENT).
abstract: BACKGROUND
  Sirolimus-eluting stent implantation improves the outcome in simple coronary artery lesions compared with bare metal stents, but there is limited evidence of their safety and efficacy when implanted in complex lesions like coronary bifurcations.
  
  
  METHODS
  SCANDSTENT was a randomized controlled study comparing implantation of sirolimus-eluting stents with bare-metal stents in patients with complex coronary artery disease. This substudy evaluates the angiographic and clinical outcome of 126 patients with lesions located in a coronary bifurcation.
  
  
  RESULTS
  The baseline characteristics of the patients were comparable: 15% had diabetes, and 1.7 stents were implanted per lesion. At follow-up, the minimum lumen diameter of the main branch was 2.35 mm in patients who received sirolimus-eluting stents compared with 1.68 mm in those who received bare-metal stents, and that of the side branch was 1.70 versus 1.19 mm (both P < .001). The late lumen loss in the main branch was 0.12 mm in the sirolimus-eluting stent group versus 0.99 mm in the bare-metal stent group and 0.03 versus 0.56 mm in the side branch (both P < .001). Thus, sirolimus-eluting stents reduced the restenosis rate from 28.3% to 4.9% in the main branch and from 43.4% to 14.8% in the side branches (both P < .001). Major adverse cardiac events occurred in 9% with sirolimus-eluting stents versus 28% with bare-metal stents (P = .01), and stent thrombosis was observed in 0% versus 9% (P = .02).
  
  
  CONCLUSIONS
  Sirolimus-eluting stent implantation improves both the angiographic and clinical outcomes considerably compared with that of bare-metal stents in patients with stenoses located in coronary bifurcations.
authors.affiliation: Skejby Sygehus, Skejby, Denmark.
authors.forename: Leif
authors.initials: L
authors.lastname: Thuesen
authors.forename: Henning
authors.initials: H
authors.lastname: Kelbaek
authors.forename: Lene
authors.initials: L
authors.lastname: Kløvgaard
authors.forename: Steffen
authors.initials: S
authors.lastname: Helqvist
authors.forename: Erik
authors.initials: E
authors.lastname: Jørgensen
authors.forename: Samir
authors.initials: S
authors.lastname: Aljabbari
authors.forename: Lars R
authors.initials: LR
authors.lastname: Krusell
authors.forename: Gunnar V H
authors.initials: GV
authors.lastname: Jensen
authors.forename: Hans E
authors.initials: HE
authors.lastname: Bøtker
authors.forename: Kari
authors.initials: K
authors.lastname: Saunamäki
authors.forename: Jens F
authors.initials: JF
authors.lastname: Lassen
authors.forename: Anton
authors.initials: A
authors.lastname: van Weert
mesh_terms: D000368:Aged; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D023903:Coronary Restenosis / Q000453:epidemiology / Q000517:prevention & control; D003331:Coronary Vessels; D016503:Drug Delivery Systems; D004867:Equipment Design; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008670:Metals; D008875:Middle Aged; D020123:Sirolimus / Q000008:administration & dosage* / Q000627:therapeutic use; D015607:Stents / Q000009:adverse effects; D013927:Thrombosis / Q000453:epidemiology / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D008670:Metals; D020123:Sirolimus